Boundless Bio Inc. (BOLD) AI Stock Analysis

• Market Cap: $25.10M
• Dividend Yield: N/A
• Average Volume (3M): 178.65K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.84
• Revenue Growth: N/A
• EPS Growth: -0.50%
• Country: US
• Employees: 64
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.58
• Shares Outstanding: 22,407,251
• 10 Day Avg. Volume: 162,533
• 30 Day Avg. Volume: 178,649
• PEG Ratio: 0.01
• Price to Book (P/B): 0.27
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.57
• Enterprise Value/Market Cap: 2.24
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -60.21
• Enterprise Value/Ebitda: -0.90
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): -2.06
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $1.00 ▼(-21.26% Downside)
• Action: Reiterated Date: 03/09/26
• Date: Action: Reiterated 03/09/26

The score is driven primarily by weak financial performance typical of an early-stage biotech (no revenue, sizable ongoing losses and negative free cash flow), despite some improvement versus 2024. Technicals also weigh on the score as the stock is below key moving averages with negative MACD. Valuation provides limited support because earnings are negative and no dividend yield is available.

Positive Factors

Proprietary ecDNA-focused platform

Boundless Bio’s explicit focus on ecDNA-driven oncogene amplification is a durable competitive angle: it targets a distinct biological driver of tumor evolution, supporting a differentiated discovery engine. A platform tied to a specific mechanism can create deep IP, higher entry barriers, and long-term program spillovers across tumor types.

Clinical advancement: IND accepted and KOMODO-1 enrolling

Regulatory acceptance of an IND and active enrollment for first-in-human KOMODO-1 represent a structural progression from preclinical to clinical development. This materially de-risks discovery-stage investment, sets a clear development milestone for proof-of-concept, and converts science into a potential near-to-intermediate term value driver for the platform.

Sufficient near-term cash runway

A stated cash runway into the second half of 2028 backed by ~$107.6M improves execution optionality for clinical readouts and minimizes immediate financing dilution. For an R&D-heavy biotech, multi-year runway reduces short-term refinancing risk and allows focus on reaching pivotal clinical milestones tied to long-term value creation.

Negative Factors

Pre-revenue with persistent cash burn

Boundless remains pre-revenue with sizable and persistent negative cash flow; TTM losses and negative free cash flow mean continued capital consumption. Over 2–6 months this structural cash burn requires either milestone execution to justify partnerships or additional financing, which can dilute shareholders or constrain strategic options if outcomes slip.

Eroding asset and equity base

Declining assets and a materially reduced equity base indicate capital has been consumed by operations. While leverage is moderate, the erosion of financial cushions reduces flexibility for opportunistic investments or to absorb clinical setbacks; negative ROE (~-47.5%) highlights persistent value dilution from operations.

Pipeline pruning and trial terminations

The decision to halt enrollment/terminate early-stage programs signals realigned priorities but also reflects clinical and market risks in prior assets. Pipeline concentration onto fewer programs raises binary risk: if the prioritized candidate underperforms, the company faces a steeper path to recover value and must redeploy R&D spend or seek outside partnerships.

Boundless Bio Inc. Business Overview & Revenue Model

Company Description

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.

How the Company Makes Money

Boundless Bio Inc. generates revenue primarily through the development and commercialization of its proprietary therapies targeting ecDNA in cancer cells. The company may receive funding through partnerships, collaborations, and licensing agreements with other pharmaceutical companies, which provide financial support for its research and development activities. Additionally, revenue could be derived from milestone payments and royalties related to the successful advancement and commercialization of its therapeutic products. Public and private funding rounds may also contribute to its financial resources, enabling ongoing research and clinical trials.

Boundless Bio Inc. Financial Statement Overview

Summary

Pre-revenue with persistent large losses (TTM net loss ~$58.2M; EBITDA/EBIT deeply negative) and continued cash burn (TTM FCF ~$-47.2M). Positives include improved loss/cash burn versus 2024 and positive equity, but assets/equity have declined, keeping overall financial strength weak.

Income Statement

BOLD remains a pre-revenue biotechnology company with $0 revenue across all reported periods, so losses are the primary driver of performance. TTM (Trailing-Twelve-Months) net loss was about $58.2M, an improvement versus the 2024 annual net loss of ~$65.4M, indicating some cost control or slower expense growth. However, profitability is still deeply negative (TTM EBITDA of roughly -$60.0M and EBIT of about -$63.6M), and gross profit is negative, underscoring an ongoing cash-burning R&D phase with limited near-term earnings visibility.

Balance Sheet

The balance sheet shows moderate leverage with TTM total debt of ~$49.0M against stockholders’ equity of ~$98.7M (debt-to-equity ~0.45). Total assets declined from ~$206.4M (2024) to ~$157.1M (TTM), and equity also fell meaningfully (from ~$150.6M in 2024 to ~$98.7M TTM), consistent with ongoing losses consuming capital. While equity is currently positive (a key improvement versus negative equity in 2021–2023), returns remain negative (TTM return on equity about -47.5%), highlighting continued pressure on the capital base.

Cash Flow

Cash generation remains weak with TTM operating cash flow of about -$46.7M and free cash flow of about -$47.2M, reflecting continued investment without revenue offset. Cash burn improved versus 2024 (operating cash flow about -$60.8M; free cash flow about -$63.4M), but TTM free cash flow still declined versus the prior period (free cash flow growth of about -10.4% as provided). Free cash flow roughly tracks net loss (TTM free cash flow to net income ~1.01), suggesting losses are translating into real cash outflow rather than being largely non-cash.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-1.25M	-1.09M	0.00	0.00	0.00
EBITDA	-62.30M	-64.28M	-53.84M	-45.53M	-24.62M
Net Income	-58.20M	-65.36M	-49.43M	-45.90M	-25.21M
Balance Sheet
Total Assets	157.06M	206.41M	129.89M	76.83M	113.72M
Cash, Cash Equivalents and Short-Term Investments	107.58M	152.11M	120.75M	66.72M	73.03M
Total Debt	49.03M	47.63M	2.19M	5.18M	377.00K
Total Liabilities	58.41M	55.77M	256.98M	158.53M	151.91M
Stockholders Equity	98.65M	150.64M	-127.08M	-81.70M	-38.19M
Cash Flow
Free Cash Flow	-47.21M	-63.38M	-47.49M	-40.66M	-25.28M
Operating Cash Flow	-46.66M	-60.84M	-46.85M	-39.60M	-23.25M
Investing Cash Flow	37.80M	-26.10M	-38.26M	16.13M	-59.28M
Financing Cash Flow	141.00K	89.82M	97.90M	126.00K	105.53M

Boundless Bio Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.27
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BOLD, the sentiment is Negative. The current price of 1.27 is above the 20-day moving average (MA) of 1.15, above the 50-day MA of 1.18, and above the 200-day MA of 1.18, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 43.51 is Neutral, neither overbought nor oversold. The STOCH value of 13.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BOLD.

Boundless Bio Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALXO	54 Neutral	$273.75M	-0.60	-118.95%	―	―	31.98%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CLGN	48 Neutral	$8.78M	-2.46	-92.74%	―	280.77%	32.82%
BRNS	46 Neutral	$27.78M	-0.43	-70.57%	―	-100.00%	-26.30%
BOLD	42 Neutral	$25.10M	-0.46	-49.73%	―	―	-0.50%
ALGS	42 Neutral	$47.77M	-1.22	-141.82%	―	-55.88%	6.14%
PLUR	40 Underperform	$33.03M	-1.06	280.42%	―	121.74%	24.75%